Myomo (MYO)
(Delayed Data from AMEX)
$3.77 USD
+0.01 (0.27%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $3.78 +0.01 (0.27%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
MYO 3.77 +0.01(0.27%)
Will MYO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MYO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MYO
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'
MYO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover
Here's Why Myomo, Inc. (MYO) Is a Great 'Buy the Bottom' Stock Now
Other News for MYO
Myomo to Participate in Two Investor Conferences in September
Myomo: Intriguing Prospects, But Preferable To Wait For A Further Pullback In The Price
The Analyst Verdict: Myomo In The Eyes Of 4 Experts
Wall Street Analysts Are Bullish on Top Healthcare Picks
Myomo Inc.: Strong Performance and Growth Prospects Justify Buy Rating